Ovarian cancer staging: does it require a gynecologic oncologist?

Area of Science:

• Gynecologic Oncology
• Medical Oncology
• Surgical Oncology

Background:

• Early-stage ovarian epithelial carcinoma requires effective treatment strategies.
• Surgical staging is a critical initial step in managing ovarian cancer.
• Treatment protocols often involve chemotherapy agents like cis-platinum, doxorubicin, and cyclophosphamide.

Purpose of the Study:

• To evaluate the survival outcomes of patients with Stages I-II invasive ovarian epithelial carcinoma.
• To determine the impact of the operating surgeon's specialty on patient survival.
• To assess the efficacy of cis-platinum, doxorubicin, and cyclophosphamide in this patient cohort.

Main Methods:

• Retrospective analysis of 47 patients with presumed Stages I-II ovarian epithelial carcinoma.
• Treatment involved intravenous cis-platinum, doxorubicin, and/or cyclophosphamide.
• Surgical staging was performed by either a gynecologic oncologist or a nononcologic surgeon.

Main Results:

• Overall 5-year actuarial survival was 73%.
• Patients staged by a gynecologic oncologist had significantly higher 5-year survival (83%) and disease-free survival (76%) compared to those staged by non-oncologists (59% and 39%, respectively).
• The specialty of the operating surgeon was identified as a significant prognostic factor (P < 0.05).

Conclusions:

• Surgical staging by a gynecologic oncologist is associated with improved survival outcomes in early-stage ovarian cancer.
• Chemotherapy regimens including cis-platinum, doxorubicin, and cyclophosphamide were utilized.
• The expertise of the surgical team plays a crucial role in patient prognosis.